% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Baccelli:119599,
      author       = {I. Baccelli$^*$ and A. Stenzinger and V. Vogel$^*$ and B.
                      M. Pfitzner and C. Klein$^*$ and M. Wallwiener and M.
                      Scharpff and M. Saini and T. Holland-Letz$^*$ and H.-P. Sinn
                      and A. Schneeweiss and C. Denkert$^*$ and W. Weichert and A.
                      Trumpp$^*$},
      title        = {{C}o-expression of {MET} and {CD}47 is a novel
                      prognosticator for survival of luminal breast cancer
                      patients.},
      journal      = {OncoTarget},
      volume       = {5},
      number       = {18},
      issn         = {1949-2553},
      address      = {[S.l.]},
      publisher    = {Impact Journals LLC},
      reportid     = {DKFZ-2017-00231},
      pages        = {8147 - 8160},
      year         = {2014},
      abstract     = {Although luminal-type primary breast cancer can be
                      efficiently treated, development of metastatic disease
                      remains a significant clinical problem. We have previously
                      shown that luminal-type circulating tumor cells (CTCs)
                      co-expressing the tyrosine-kinase MET and CD47, a ligand
                      involved in cancer cell evasion from macrophage scavenging,
                      are able to initiate metastasis in xenografts. Here, we
                      investigated the clinical relevance of MET-CD47
                      co-expression in 255 hormone receptor positive breast tumors
                      by immunohistochemistry and found a 10.3- year mean
                      overall-survival difference between MET-CD47 double-positive
                      and double-negative patients (p<0.001) MET-CD47
                      co-expression defined a novel independent prognosticator for
                      overall-survival by multivariate analysis (Cox proportional
                      hazards model: HR: 4.1, p<0.002) and CD47 expression alone
                      or in combination with MET was strongly associated with
                      lymph node metastasis. Furthermore, flow cytometric analysis
                      of metastatic patient blood revealed consistent presence of
                      MET+CD47+ CTCs (range 0.8 - $33.3\%$ of CTCs) and their
                      frequency was associated with increased metastatic spread.
                      Finally, primary uncultured CTCs with high MET+CD47+ content
                      showed an enhanced capacity to initiate metastasis in mice.
                      Detection and targeting of MET and CD47 may thus provide a
                      rational basis for risk stratification and treatment of
                      patients with luminal-type breast cancer.},
      keywords     = {Antigens, CD47 (NLM Chemicals) / Biomarkers, Tumor (NLM
                      Chemicals) / CD47 protein, human (NLM Chemicals) / MET
                      protein, human (NLM Chemicals) / Proto-Oncogene Proteins
                      c-met (NLM Chemicals)},
      cin          = {A010 / C060 / L101 / L201},
      ddc          = {610},
      cid          = {I:(DE-He78)A010-20160331 / I:(DE-He78)C060-20160331 /
                      I:(DE-He78)L101-20160331 / I:(DE-He78)L201-20160331},
      pnm          = {311 - Signalling pathways, cell and tumor biology
                      (POF3-311)},
      pid          = {G:(DE-HGF)POF3-311},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:25230070},
      pmc          = {pmc:PMC4226673},
      doi          = {10.18632/oncotarget.2385},
      url          = {https://inrepo02.dkfz.de/record/119599},
}